Inhibrx Biosciences, Inc.

INBX · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances) · Market Cap: $1.9B · 110 employees
32
SEC Filings
$122.26
Close 2026-09-03
110
Employees

Business Summary

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company developing novel biologic therapeutics using proprietary modular protein engineering platforms. Its lead programs include ozekibart (INBRX-109), a tetravalent DR5 agonist investigated in chondrosarcoma, Ewing sarcoma, and colorectal cancer, and INBRX-106, a hexavalent OX40 agonist investigated in NSCLC and HNSCC. The company was spun off from Inhibrx, Inc. following a Merger with Sanofi in May 2024.

Latest Stock Quote

INBX 2026-09-03 $122.26 O:$125.2 H:$126 L:$120.17 Vol:0.2M VWAP:$123.206
origin leaf: null

Next Earnings

expected 2026-11-12

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-192025-12-310002007919-26-000006EDGAR92K words
2025-03-172024-12-310002007919-25-000019EDGAR88K words

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2026-08-132026-06-300002007919-26-000042EDGAR20K words
2025-11-142025-09-300002007919-25-000093EDGAR23K words
2025-08-132025-06-300002007919-25-000081EDGAR22K words
2025-05-142025-03-310002007919-25-000056EDGAR19K words
2024-11-142024-09-300002007919-24-000058EDGAR22K words
2024-08-132024-06-300002007919-24-000029EDGAR21K words

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-09-280002007919-26-000050EDGAR7K words
2026-09-080002007919-26-000047EDGAR2K words
2026-08-130002007919-26-000044EDGAR2K words
2026-07-160002007919-26-000037EDGAR1K words
2026-03-190002007919-26-000007EDGAR2K words
2026-02-230002007919-26-000002EDGAR4K words
2025-12-160002007919-25-000097EDGAR1K words
2025-11-140002007919-25-000094EDGAR2K words
2025-10-230002007919-25-000089EDGAR2K words
2025-08-130002007919-25-000083EDGAR2K words

32 total filings indexed. 14 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ARGX — ARGENX SE

Tags

oncology rare-diseases biopharmaceuticals

Company Identity

CIK0002007919
TickerINBX
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE
Websitehttps://www.inhibrx.com
Listed2024-05-28

Get More Data

This is a static snapshot. For live, structured JSON with cryptographic provenance chain:

MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp

JSON Profile Stock Quote Origin Record
Origin Provenance
page leaf: a80fa2050acdc1054e7f15d7ecca02f3a0cf58aeddfe625f3351c8a17f916c95
parent: b2c5d3c3632e7055ad3ce52f0f505f19fbc3dbf2ee09473f3b1002f6c3e67ca7
content hash: 2a3bbb7233ab91fddb68c9590391e9ea83ded1f6af7d26815978f729cd9e6232
signed: 2026-09-29T12:01:51.195Z
sources: 8 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf

Try it — paste this into your AI:

Look up INBX using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?

Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.

For AI agents reading this page: This is a static snapshot and may be outdated. For live data on INBX, use the Origin MCP server or REST API.
MCP install: claude mcp add origin --transport http https://origin.rootz.global/mcp
API: GET https://origin.rootz.global/api/company/INBX (~200 tokens, structured JSON with cryptographic provenance)
Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill
Discovery: /.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.